Putnam Investments LLC Has $1,058,000 Holding in Neurocrine Biosciences, Inc. (NBIX)

Putnam Investments LLC Has $1,058,000 Holding in Neurocrine Biosciences, Inc. (NBIX)

Putnam Investments LLC boosted its position in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 8.8% during the fourth quarter, Holdings Channel reports. The institutional investor owned 27,348 shares of the company’s stock after buying an additional 2,222 shares during the period. Putnam Investments LLC’s holdings in Neurocrine Biosciences were worth $1,058,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently made changes to their positions in NBIX. Royal Bank of Canada boosted its stake in Neurocrine Biosciences by 3.1% in the second quarter. Royal Bank of Canada now owns 477,152 shares of the company’s stock worth $21,686,000 after buying an additional 14,449 shares during the last quarter. BNP Paribas Arbitrage SA boosted its stake in Neurocrine Biosciences by 13.6% in the third quarter. BNP Paribas Arbitrage SA now owns 14,472 shares of the company’s stock worth $733,000 after buying an additional 1,736 shares during the last quarter. First Mercantile Trust Co. boosted its stake in Neurocrine Biosciences by 94.9% in the third quarter. First Mercantile Trust Co. now owns 3,897 shares of the company’s stock worth $197,000 after buying an additional 1,897 shares during the last quarter. Creative Planning boosted its stake in Neurocrine Biosciences by 0.7% in the third quarter. Creative Planning now owns 5,338 shares of the company’s stock worth $270,000 after buying an additional 38 shares during the last quarter. Finally, Fox Run Management L.L.C. bought a new stake in Neurocrine Biosciences during the third quarter worth approximately $218,000. 97.60% of the stock is owned by institutional investors and hedge funds.

Neurocrine Biosciences, Inc. (NASDAQ:NBIX) opened at 43.89 on Tuesday. The stock’s 50 day moving average is $43.78 and its 200-day moving average is $45.46. Neurocrine Biosciences, Inc. has a one year low of $32.91 and a one year high of $55.15. The firm’s market capitalization is $3.82 billion.

Neurocrine Biosciences (NASDAQ:NBIX) last posted its quarterly earnings results on Tuesday, February 14th. The company reported ($0.51) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.56) by $0.05. During the same quarter in the prior year, the business earned ($0.34) EPS. On average, analysts anticipate that Neurocrine Biosciences, Inc. will post ($2.28) EPS for the current fiscal year.

NBIX has been the subject of a number of research reports. Citigroup Inc initiated coverage on shares of Neurocrine Biosciences in a report on Tuesday, November 22nd. They issued a “market perform” rating and a $55.00 price target for the company. They noted that the move was a valuation call. Oppenheimer Holdings Inc. initiated coverage on shares of Neurocrine Biosciences in a report on Tuesday, November 22nd. They issued a “market perform” rating and a $55.00 price target for the company. Piper Jaffray Companies restated an “overweight” rating and issued a $96.00 price target on shares of Neurocrine Biosciences in a report on Wednesday, December 7th. Leerink Swann restated an “outperform” rating and issued a $70.00 price target on shares of Neurocrine Biosciences in a report on Friday, December 23rd. Finally, Robert W. Baird restated a “buy” rating and issued a $66.00 price target on shares of Neurocrine Biosciences in a report on Sunday, January 8th. One equities research analyst has rated the stock with a sell rating, one has issued a hold rating and fifteen have issued a buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $67.00.

In related news, Director William H. Rastetter sold 10,750 shares of the company’s stock in a transaction on Wednesday, February 1st. The shares were sold at an average price of $42.28, for a total transaction of $454,510.00. Following the completion of the sale, the director now directly owns 25,000 shares in the company, valued at approximately $1,057,000. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, insider Christopher Flint Obrien sold 1,750 shares of the company’s stock in a transaction on Tuesday, January 10th. The shares were sold at an average price of $43.35, for a total transaction of $75,862.50. Following the sale, the insider now owns 31,794 shares of the company’s stock, valued at $1,378,269.90. The disclosure for this sale can be found here. Insiders have sold a total of 32,816 shares of company stock valued at $1,387,036 over the last quarter. 4.80% of the stock is currently owned by company insiders.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc is engaged in discovering and developing pharmaceuticals, in diseases with unmet medical needs, through its research and development (R&D) platform, focused on neurological and endocrine based diseases and disorders. Its three lead late-stage clinical programs are elagolix, which is a gonadotropin-releasing hormone (GnRH) antagonist for endometriosis and uterine fibroids; INGREZZA (valbenazine), which is a vesicular monoamine transporter 2 (VMAT2) inhibitor, for the treatment of movement disorders, and opicapone, which is a selective catechol-O-methyltransferase inhibitor that is an adjunct therapy to preparations of levodopa/Dihydroxyphenylalanine (DOPA) decarboxylase inhibitors for adult patients with Parkinson’s disease.

Want to see what other hedge funds are holding NBIX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Neurocrine Biosciences, Inc. (NASDAQ:NBIX).

Related posts

Leave a Comment